Dr. Reddy’s Labs to acquire eight U.S. drugs from Teva & Allergan for $350m

India-based pharma firm drugmaker Dr Reddy’s Laboratories Ltd has reached an agreement to acquire eight generic brands of drugs from Teva Pharmaceutical Industries and Allergan Plc for $350m in cash to bolster its U.S. business.

The deal is part of Teva Pharma’s plan to divest certain brands of generics in the U.S. market to gain regulatory approval for its $40.5bn merger with Allergan.

The deal consists of generic drugs awaiting U.S. approval, and some that are already on the market, including “complex generic products across diverse dosage forms”.

The branded versions of drugs under the deal had U.S. sales of about $3.5bn in the year to April 2016 (Source: IMS Health).

Dr Reddy’s plans to finance the deal with cash on hand and available borrowings under existing credit facilities.

Source: Reuters

Pfizer, Allergan scrap $160bn deal after U.S. tax rule change

U.S. drugmaker Pfizer Inc. and Ireland-based Allergan Plc terminated their $160bn merger on Wednesday, due to a new U.S. Treasury tax rule which aims to block deals when companies move overseas to reduce taxes.

The merger would have allowed Pfizer to cut its tax bill by an estimated $1bn a year by domiciling in Ireland, where tax rates are lower.

Allergan Chief Executive Brent Saunders stated that the new Treasury rule would not stop the company from doing other stock-based acquisitions in the next two quarters of 2016.

Separately, Allergan would now move ahead with plans for its $40.5bn sale of its generic drug business to Israel’s Teva Pharmaceutical Industries. It expects the transaction to close by June 2016.

Also, Pfizer would decide this year, whether it wants to split off its generic medicines into a separate business. It had put off making that decision until 2019 after announcing its deal with Allergan last November.

Pfizer will pay Allergan $150m to reimburse expenses from its deal.

Source: Reuters